Pharmacological classification of hydroxychloroquine

Discussion in 'Chloroquine' started by woker, 25-Feb-2020.

  1. KeZZ New Member

    Pharmacological classification of hydroxychloroquine


    Falciparum Discontinue in 6 months if improvement is inadequate Use in patients with psoriasis may precipitate a severe attack of psoriasis; use with caution Postmarketing cases of life-threatening and fatal cardiomyopathy reported with use of hydroxychloroquine as well as of chloroquine Irreversible retinal damage observed in some patients who had received hydroxychloroquine sulfate; significant risk factors for retinal damage include daily doses of hydroxychloroquine sulfate greater than 6.5 mg/kg (5 mg/kg base) of actual body weight, durations of use greater than five years, subnormal glomerular filtration, use of some concomitant drug products such as tamoxifen citrate and concurrent macular disease Ocular examination is recommended within first year of therapy; baseline exam should include: best corrected distance visual acuity (BCVA), an automated threshold visual field (VF) of the central 10 degrees (with retesting if an abnormality is noted), and spectral domain ocular coherence tomography (SD-OCT) For individuals with significant risk factors (daily dose of hydroxychloroquine sulfate 5.0 mg/kg base of actual body weight, subnormal glomerular filtration, use of tamoxifen citrate or concurrent macular disease) monitoring should include annual examinations which include BCVA, VF and SD-OCT; for individuals without significant risk factors, annual exams can usually be deferred until five years of treatment In individuals of Asian descent, retinal toxicity may first be noticed outside macula; in patients of Asian descent, it is recommended that visual field testing be performed in central 24 degrees instead of central 10 degrees Hydroxychloroquine should be discontinued if ocular toxicity is suspected and patient should be closely observed given that retinal changes (and visual disturbances) may progress even after cessation of therapy Hepatic disease or alcoholism Glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with hemolysis and renal impairment; use with caution Dermatologic reactions to hydroxychloroquine may occur Patients are prone to dermatitis outbreaks Signs or symptoms of cardiac compromise have appeared during acute and chronic treatment; clinical monitoring for signs and symptoms of cardiomyopathy is advised, including use of appropriate diagnostic tools such as ECG to monitor patients for cardiomyopathy during therapy; if cardiotoxicity is suspected, prompt discontinuation may prevent life-threatening complications Not for administration with other drugs that have potential to prolong QT interval; hydroxychloroquine prolongs QT interval; ventricular arrhythmias and torsades de pointes reported in patients taking hydroxychloroquine Skeletal muscle myopathy or neuropathy leading to progressive weakness and atrophy of proximal muscle groups, depressed tendon reflexes, and abnormal nerve conduction, reported; muscle and nerve biopsies have been associated with curvilinear bodies and muscle fiber atrophy with vacuolar changes; assess muscle strength and deep tendon reflexes periodically in patients on long-term therapy Suicidal behavior rarely reported in patients treated with hydroxychloroquine Hematologic reactions (including aplastic anemia) and agranulocytosis may occur May exacerbate heart failure Shown to cause severe hypoglycemia including loss of consciousness that could be life threatening in patients treated with or without antidiabetic medications; warn patients about risk of hypoglycemia and associated clinical signs and symptoms; patients presenting with clinical symptoms suggestive of hypoglycemia during treatment should have their blood glucose checked and treatment reviewed as necessary A reduction in dosage may be necessary in patients with hepatic or renal disease, as well as in those taking medicines known to affect these organs Use with caution in patients with hepatic disease or alcoholism or in conjunction with known hepatotoxic drugs Consider discontinuing therapy if any severe blood disorder such as aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia, which is not attributable to the disease under treatment appears; perform periodic blood cell counts if patients are given prolonged therapy Pregnancy category: C Lactation: Drug is concentrated in breast milk (American Academy of Pediatrics committee states that it is compatible with nursing) A: Generally acceptable. Contact the applicable plan provider for the most current information. Controlled studies in pregnant women show no evidence of fetal risk. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. Animal studies show risk and human studies not available or neither animal nor human studies done.

    Hydroxychloroquine sulfate t What does plaquenil do to your body

    Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Rainsford KD1, Parke AL2, Clifford-Rashotte M3, Kean WF45. Irreversible retinal damage observed in some patients who had received hydroxychloroquine sulfate; significant risk factors for retinal damage include daily doses of hydroxychloroquine sulfate greater than 6.5 mg/kg 5 mg/kg base of actual body weight, durations of use greater than five years, subnormal glomerular filtration. Hydroxychloroquine sulfate greater than 6.5 mg/kg 5 mg/kg base of actual body weight, durations of use greater than five years, subnormal glomerular filtration, use of some concomitant drug products such as tamoxifen citrate and concurrent macular disease.

    Unknown; may impair complement-dependent antigen-antibody reactions; inhibits locomotion of neutrophils and chemotaxis of eosinophils Increases p H and interferes with lysosomal degradation of hemoglobin, which in turn interferes with digestive vacuole function Bioavailability: Rapid and complete absorption Onset: May take 4-6 months to show response; peak response takes several months (rheumatic disease) Duration: Unknown Peak plasma time: 1-3 hr Protein bound: 55% Metabolites: Desethylhydroxychloroquine, desethylchloroquine Half-life: 32-50 days Excretion: Urine (60%) The above information is provided for general informational and educational purposes only. D: Use in LIFE-THREATENING emergencies when no safer drug available.

    Pharmacological classification of hydroxychloroquine

    Plaquenil Hydroxychloroquine Uses, Dosage, Side Effects., Plaquenil hydroxychloroquine sulfate dosing, indications.

  2. Plaquenil sun spots
  3. Plaquenil toxicity macula powerpoint
  4. Plaquenil cardiomyopathy cardiac mri
  5. Hydroxychloroquine is excreted both renally and hepatically. The amount of hydroxychloroquine excreted in the urine as unchanged drug ranges from 6% to 60% median 23%, and 17% is excreted in the urine as metabolized drug.

    • Hydroxychloroquine Information for Providers AIDSinfo.
    • PLAQUENIL HYDROXYCHLOROQUINE SULFATE TABLETS, USP DESCRIPTION.
    • Hydroxychloroquine sulfate C18H28ClN3O5S - PubChem.

    Treatment of uncomplicated P. falciparum, P. malariae, P. orale, and P. vivax malaria. Prophylaxis of malaria in areas with no chloroquine resistance. Not for treating complicated malaria. Not effective against chloroquine- or hydroxychloroquine-resistant strains. Not for preventing relapses of P. vivax or P. ovale. The antimalarial agents chloroquine and hydroxychloroquine have been used widely for the treatment of rheumatoid arthritis and systemic lupus erythematosus. These compounds lead to improvement of clinical and laboratory parameters, but their slow onset of action distinguishes them from glucocorticoids and nonsteroidal antiinflammatory agents. The optimal treatment of RA requires a comprehensive program that combines medical, social, and emotional support for the patient. It is essential that the patient and the patient’s family be educated about the nature and course of the disease. Treatment options include medications, reduction of joint stress.

     
  6. foma Moderator

    Plaquenil (hydroxychloroquine) is a member of the antimalarial quinolines drug class and is commonly used for Dermatomyositis, Lyme Disease - Arthritis, Malaria, and others. The cost for Plaquenil oral tablet 200 mg is around ,100 for a supply of 100 tablets, depending on the pharmacy you visit. Lowest Plaquenil Price Comparison & Free Coupons at. Plaquenil 200mg Hydroxychloroquine - InhousePharmacy.vu Hydroxychloroquine Uses, Dosage & Side Effects -
     
  7. The oils from the aerial parts showed good activity against Gram-positive bacteria. International Journal of Antimicrobial Agents Antiviral Activity of Chloroquine against Human Coronavirus. Chloroquine & Hydroxychloroquine supporting chemo.
     
  8. Glen XenForo Moderator

    Chloroquine and primaquine combining old drugs as a new. There is compelling evidence that CQ resistance arises from mutations in PfCRT 14, 15, although the mechanism of PfCRT-determined resistance remains contentious. However, bioinformatics studies have revealed the protein to be a member of the drug/metabolite effluxer family of the drug/metabolite transporter superfamily 16, 17.

    Animal Drugs @ FDA
     
  9. Yucca Guest

    Ocular Changes Induced by Long-Term Hydroxychloroquine Plaquenil Therapy OCULAR CHANGES INDUCED BY LONG-TERM H Y D R O X Y C H L O R O Q U I N E PLAQUENIL THERAPY ROBERT V. SHEARER, M. D. AND EDMUND L. DUBOIS, M. D. Los Angeles, California Hydroxychloroquine Plaquenil has been employed for the treatment of discoid and systemic lupus erythematosus, rheuma toid arthritis and light-sensitive eruptions since 1955.

    Plaquenil Risk Calculators